Trained dogs can smell Parkinson's disease before symptoms show up, study finds
In a new study from the University of Bristol, dogs were found to detect Parkinson's disease well before symptoms appear.
Previous research has shown that people with Parkinson's have increased amounts of sebum — an oily, waxy substance with a distinctively musky odor — on the skin.
In the new study, two dogs that had been trained on more than 200 odor samples were presented with skin swabs from 130 people with Parkinson's and 175 people without the disease, according to a press release.
The dogs — a golden retriever named Bumper and a black labrador named Peanut — were rewarded for positively identifying Parkinson's samples and for ignoring negative ones.
The dogs showed sensitivity of up to 80% — which means they identified people who had the disease 80% of the time.
They achieved specificity of up to 98%, which is how good they were at ruling out people who did not have Parkinson's.
"The dogs … showed there is an olfactory signature distinct to patients with the disease."
The University of Bristol collaborated with Medical Detection Dogs and the University of Manchester on the study, which was published in The Journal of Parkinson's Disease on July 15.
While there is no early screening available for Parkinson's, some early warning signs can appear years or even decades before diagnosis, according to experts.
"Identifying diagnostic biomarkers of PD, particularly those that may predict development or help diagnose disease earlier, is the subject of much ongoing research," said lead study author Nicola Rooney, associate professor at Bristol Veterinary School at the University of Bristol, in the release.
"The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," she went on.
"Sensitivity levels of 70% and 80% are well above chance, and I believe that dogs could help us to develop a quick, non-invasive and cost-effective method to identify patients with Parkinson's disease."
Claire Guest, chief scientific officer at Medical Detection Dogs in the U.K., reiterated that the study confirmed dogs can "very accurately" detect disease.
"Timely diagnosis is key, as subsequent treatment could slow down the progression of the disease and reduce the intensity of symptoms," she said in the release.
Perdita Barran, professor of mass spectrometry at The University of Manchester, said the study "adds to the growing body of evidence showing that simple, non-invasive skin swabs can be used to diagnose Parkinson's disease, offering a faster and more accessible method for early detection."
For more Health articles, visit www.foxnews.com/health
Looking ahead, the team plans to conduct longer-term studies to assess dogs' capacity to detect Parkinson's before diagnosis.
The Michael J. Fox Foundation and Parkinson's UK provided funding for this study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Changing regulations impact medical device market entry strategies
The medical devices industry is always undergoing significant regulatory changes. In the EU and UK there have been new frameworks introduced recently, and as a result the medical device industry is consistently navigating a complex and evolving regulatory framework that has implications on medical device company market strategies. The EU Medical Devices Regulation (MDR) came into effect on 26 May 2021. The regulation introduced several changes to medical device regulation in Europe, including stronger market surveillance, establishing explicit responsibilities for manufacturers, improved traceability, a central database for comprehensive information on medical products, and high-risk device assessment. Additionally, in July 2025, the Competent Authorities for Medical Devices and the Head of Medicines Agency issued a statement advocating for significant medical device regulation reforms in the EU. Specifically, they are advocating for improved coordination, governance, and centralisation of regulatory activities in the EU. Similarly, in the UK, new Post-Market Surveillance regulations have taken effect in June 2025. The new regulations require device manufacturers to track the safety and performance of products to help identify safety issues early. The regulations will ensure manufacturers have a system in place to monitor devices once in use, collect safety data, report serious incidents, and take action quickly when any issues arise. These changes and expansions mean that manufacturers need to navigate complex landscapes of regulations that govern various aspects of medical device production. The need to comply with these regulations can lead to increased operational costs and may limit the ability to rapidly introduce new products. Changes and expansions in regulations can significantly impact market entry strategies. The evolving landscape often results in longer timelines to get necessary approvals, ultimately hindering a company's ability to enter the market with new products quickly. This can divert resources from other critical areas such as research and development or marketing, potentially impacting overall competitiveness. Due to the complexity of regulatory requirements, companies may consider forming strategic partnerships with local companies that have established regulatory pathways. This can facilitate smoother market entry and compliance with local laws. Companies should establish robust compliance programmes to monitor adherence to both domestic and international regulations. Companies that have proactively adapted their product development processes to comply with new regulations tend to perform better. For example, companies that invested in understanding the MDR and preemptively adjusted their clinical trial protocol to align with the requirements likely gained a competitive edge. The implications of medical device regulations on market entry strategies are profound. Companies should be prepared to navigate an increasingly complex regulatory environment. Successful market entry strategies involve a combination of compliance, strategic partnerships, technological innovation, and localised market research. "Changing regulations impact medical device market entry strategies" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. Related EU pharma chief calls for European Nasdaq to boost biotech innovation Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.
Business Wire
an hour ago
- Business Wire
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. Share Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.
